IDEMIA
19.7.2021 11:28:07 CEST | Business Wire | Press release
IDEMIA Group announced today the appointment of Dominique Cerutti as Group Board Member, effective July 1st 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210719005297/en/
Dominique Cerutti comes with over 35 years of experience in Technology, R&D and Engineering services. He has held several CEO positions of leading technology companies and his expertise in growing large-scale international businesses will be a significant contribution to IDEMIA’s strategic vision.
“Dominique is a very seasoned leader with a demonstrated track record in transforming and growing large-scale international technology businesses. He will be instrumental for the Group moving forward”, said Pierre Barrial, IDEMIA Group President & CEO.
“We are pleased to welcome Dominique Cerutti to the IDEMIA Board. With more than 35 years of experience, Dominique is an undisputed expert in security and technology and a tremendous addition to IDEMIA’s Board” said Yann Delabrière, Chairman of the Board
“I couldn’t be more honored and thrilled to be joining IDEMIA, global leader in Augmented Identity, at an exciting time in its development. I look forward to offering strategic guidance and contributing to making the world a safer place”, said Dominique Cerutti.
NOTE TO EDITORS – Dominique Cerutti’s biography
Starting June 2015, Dominique Cerutti spent 5 years as Chief Executive Officer of the Altran group. He was also Chairman of the Altran Board from June 2015 to April 2020, until the acquisition of the company by Capgemini. Under his leadership, Altran has become the undisputed global leader in Engineering and R&D services, growing from 20,000 to more than 50,000 engineers worldwide, with revenues up to 3.2bn euros. He has deeply transformed the company by adapting the organization, promoting new business models and driving major acquisitions, enabling Altran to stay ahead of the competition, drive the market and reshape the global ER&D industry. Fervent advocate of the acquisition by Capgemini, he has worked hand in hand with the Group to make the integration a success and stepped down at the end of 2020.
Before joining Altran, Dominique Cerutti was CEO and Chairman of the Managing Board of Euronext, the leading pan-European exchange. He established Euronext as an independent company and the leading pan-European Exchange, through a successful IPO following the acquisition of NYSE-Euronext by the ICE Group in November 2013 and the subsequent demerger of Euronext from NYSE. He led the strategic repositioning of Euronext as the premier pan-European financing center. He and his team have been deeply involved with the correction of the previously biased EU financial markets regulation, promoting transparency and increased investors protections within the EU financial markets.
He was previously President and Deputy CEO, and a board member of New-York Stock Exchange (NYSE), the world’s leading exchange Group.
Dominique Cerutti also spent over 20 years at IBM in an international career, where he contributed to the company’s strategic transformation. In particular, he served as Chief Executive Officer of IBM Global Services for the Europe, Middle East, Africa, and later for IBM Europe, after being Executive Assistant to Lou Gerstner, Chairman and CEO of IBM.
He held various Board positions at LCH-Clearnet, Euromed Business School, New-York Stock Exchange, Altran, Euronext, Genes’ink.
Since March 2021, he is chairman of Adarma’s Board, one of the largest independent security services companies in the UK.
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space. Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20210719005297/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Winston Taylor Completes Historic Transatlantic Combination1.6.2026 13:01:00 CEST | Press release
Transatlantic powerhouse law firm established for the businesses, people, and markets driving capital and innovation Winston Taylor announces today that Winston & Strawn and Taylor Wessing’s U.K.-led business have officially launched as a single combined firm, creating a premier transatlantic law firm built for the needs of the businesses, people, and markets driving capital and innovation. One of the largest transatlantic firms, with more than 1,400 lawyers spanning the United States, the United Kingdom, Europe, Latin America, and the Middle East, Winston Taylor is built to meet clients’ evolving global needs for counsel. “As Winston Taylor, we are centered on a client-first approach and will be working shoulder to shoulder with our clients at the cutting edge of industry and ingenuity,” said Chairman Steve D’Amore. “With that common purpose, we are leveraging both strength and scale by integrating our teams and offices at record speed, working at pace to create a firm that is aligned
Kinaxis Appoints Kristin Russel as Chief Marketing Officer1.6.2026 13:00:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced the appointment of Kristin Russel as Chief Marketing Officer (CMO). Russel will lead Kinaxis’ global marketing organization, overseeing marketing strategy, corporate and market positioning, digital and brand marketing, communications and go-to-market initiatives. Russel will also take the main stage at Kinexions, where she will discuss practical steps organizations can take to move from decisions to outcomes in an increasingly complex operating environment. A tenured marketing executive and recognized industry leader, Russel brings deep experience scaling technology companies and building high impact brands. She joins Kinaxis from symplr, where she served as Chief Marketing Officer and led the development and execution of the company’s comprehensive marketing strategy across branding, digital and product marketing, public relations, community outreach programs, channel partne
Samsung Electronics Begins Shipment of Industry-First HBM4E Samples1.6.2026 12:57:00 CEST | Press release
Samsung's 12-layer HBM4E achieves speeds of up to 16Gbps with improved energy efficiency and thermal performanceProven processes from HBM4 production experience and technology enhancements support increasingly demanding next-generation AI workloads Samsung Electronics, a global leader in advanced memory technology, has begun shipping the industry's first 12-layer HBM4E samples to major global customers, further strengthening its leadership in the next-generation HBM market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260601979564/en/ Samsung's 12-layer HBM4E Following the industry’s first mass production and commercial shipment of its industry-leading HBM4 earlier this year, Samsung now extends its HBM roadmap with the introduction of HBM4E samples, addressing the rapidly evolving demands of AI computing and hyperscale infrastructure. "Following the successful mass production of HBM4, Samsung has once again demonstrated i
GIGABYTE Showcases Full-Stack AI Infrastructure from Rack-Scale Systems to Real-World Deployment at COMPUTEX 20261.6.2026 12:30:00 CEST | Press release
Following the introduction of its "Future Landing" vision, GIGABYTE Technology, a global leader in high-performance computing and AI infrastructure, brings that vision to life at COMPUTEX 2026 through a comprehensive showcase of systems, software, and real-world deployments that demonstrate how AI infrastructure is built, deployed, and operated at scale. From rack-scale AI factories and modular data centers to Physical AI workflows, clinical AI applications, and on-prem AI agents, GIGABYTE demonstrates how AI infrastructure moves beyond planning and into production. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525486787/en/ Rack-Scale Infrastructure, Validated for AI Factories At the foundation of “Future Landing” is GIGABYTE’s expanding portfolio of rack-scale AI infrastructure designed for next-generation AI factories. Among the latest highlights is the NVIDIA Vera Rubin NVL72, showcased as part of GIGABYTE’s broader
BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 20261.6.2026 12:00:00 CEST | Press release
Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal developmentCompany to host investor webcast showcasing momentum across solid tumor pipeline BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. Data from three differentiated BeOne pipeline assets will be presented, including: CDK4 inhibitor (BGB-43395) (poster presentation): First disclosure of anti-tumor activity in first-line (1L) HR+/HER2- metastatic breast cancer. B7-H4 ADC (BG‑C9074) (rapid oral presentation): Phase 1 dose-escalation and safety expansion data in adva
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
